Eldridge George A 4
4 · Aerovate Therapeutics, Inc. · Filed Apr 12, 2024
Insider Transaction Report
Form 4
Eldridge George A
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-04-10$2.14/sh+7,500$16,050→ 9,460 total - Sale
Common Stock
2024-04-10$26.77/sh−6,729$180,139→ 2,731 total - Sale
Common Stock
2024-04-10$27.56/sh−771$21,252→ 1,960 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-10−7,500→ 43,763 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (7,500 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.32 to $27.315, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.35 to $27.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.